Cell Therapy at a Crossroads

Over the past decade, cell therapy has emerged as one of the most transformative forces in precision medicine, delivering astonishing clinical results—particularly in hematologic malignancies and autoimmune diseases. But the triumphs have not come without caveats. Toxicities remain a serious concern, and the logistical complexity and cost of autologous manufacturing have turned access into a luxury few patients can afford. Cell therapy, for all its promise, has largely remained an option for the privileged few.

Enter Artiva Biotherapeutics, a clinical-stage biotech pushing to democratize cell therapy by reimagining its very foundations. At the heart of their strategy is AlloNK ® , a non-genetically modified, cryopreserved natural killer (NK) cell therapy designed to bypass the inherent